CP-532,903
From Self-sufficiency
| CP-532,903 | |
|---|---|
| File:CP532903 structure.png | |
| (2S,3S,4R,5R)-3-amino-5-[6-(2,5-dichlorobenzylamino)purin-9-yl]-4-hydroxytetrahydrofuran-2-carboxylic acid methylamide | |
| Other names CP-532,903 | |
| style="background: #F8EABA; text-align: center;" colspan="2" | Identifiers | |
| CAS number | 457612-59-8 |
| SMILES | Script error: No such module "collapsible list". |
| style="background: #F8EABA; text-align: center;" colspan="2" | Properties | |
| Molecular formula | C18H19Cl2N7O3 |
| Molar mass | 452.294 |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
CP-532,903 is a selective adenosine A3 subtype receptor agonist. It has antiinflammatory effects and has been shown to reduce superoxide generation in damaged tissues,[1] and protects against tissue damage following myocardial ischemia,[2] mediated via an interaction with ATP-sensitive potassium channels.[3]
 |
This pharmacology-related article is a stub. You can help ssf by expanding it. |
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
- ↑ van der Hoeven D, Wan TC, Auchampach JA. Activation of the A(3) adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils. Molecular Pharmacology. 2008 Sep;74(3):685-96. PMID 18583455
- ↑ Tracey WR, Magee WP, Oleynek JJ, Hill RJ, Smith AH, Flynn DM, Knight DR. Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. American Journal of Physiology. Heart and Circulatory Physiology. 2003 Dec;285(6):H2780-7. PMID 12919933
- ↑ Wan TC, Ge ZD, Tampo A, Mio Y, Bienengraeber MW, Tracey WR, Gross GJ, Kwok WM, Auchampach JA. The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel. Journal of Pharmacology and Experimental Therapeutics. 2008 Jan;324(1):234-43. PMID 17906066
